INTRODUCTION AND OBJECTIVES:
There is no consensus on the optimal management of patients experiencing local recurrence after Focal Therapy(FT) for Prostate Cancer(PCa). Options include Surveillance, repeat focal ablation or transition to whole gland treatment, including Robotic Assisted Radical Prostatectomy(S-RALP) and radiotherapy(RT). In order to optimize treatment selection in this population, we sought to determine the risk factors for disease recurrence after S-RALP for failed FT.
METHODS: Multi-centre cohort study of 82 consecutive patients submitted to S-RALP post FT. In all patients metastatic disease was excluded with a pelvic MRI, bone scan and/or PET-CT. A Cox Regression multivariate model was constructed to determine the impact of risk factors for biochemical recurrence after salvage surgery post FT. CONCLUSIONS: Men identified as having infield recurrence after FT appear to have phenoypically aggressive disease and as such should probably transition early to whole gland radical therapy and arguably utilising surgery as part of a multimodal approach to their disease, rather than having a further attempt at FT in the in-field recurrence.
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MP78-15 CONCOMITANT FOCAL THERAPY AND ROBOTIC LYMPHADENECTOMY IN PROSTATE CANCER: INITIAL SERIES
Akbar Ashrafi*, Andre Luis de Castro Abreu, Alessandro Tafuri, Giovanni Cacciamani, Aliasger Shakir, Matthew Winter, Daniel Park, Prakash Gill, Inderbir Gill, Alhambra, CA INTRODUCTION AND OBJECTIVES: Pelvic lymph node dissection (PLND) remains the gold standard for nodal staging in prostate cancer (PCa). Radical prostatectomy for intermediate-high risk prostate cancer (PCa) routinely incorporates regional lymphadenectomy. Current guidelines recommend PLND during radical prostatectomy in men at risk of lymph node involvement (LNI). However, during high-intensity focused ultrasound (HIFU) ablation for similar risk PCa, the regional lymph nodes remain untreated. To address this issue, we explored concomitant robotic lymphadenectomy (rLND) during focal hemi-gland HIFU (fHIFU) for intermediate-high risk PCa.
METHODS: Ten highly-selected men with unilateral Gleason Grade (GG) > 1 PCa (90% had GG 3-5 PCa; 50% had recurrent PCa) were identified from our IRB-approved database between 07/2016 and 09/2018. LND was indicated for any recurrent PCa or >5% risk of lymph node invasion (LNI) for primary PCa on validated nomograms. Patients had mpMRI and 12-core systematic and targeted fusion prostate biopsy, and work-up to exclude bony or visceral metastasis. We evaluated feasibility, safety and perioperative outcomes. Complications were recorded up to 30 days using Clavien Classification System. RESULTS: All patients had unilateral Grade Group (GG) 2 or higher disease; 9 patients (90%) had unilateral GG 3-5 disease. No patients had > GG 1 PCa in the contralateral lobe. Five patients had primary and 5 had recurrent PCa. Median LNI risk was 11%; no patient had bony/visceral metastasis. Concomitant fHIFU and rLND was technically successful in all patients. Median total operating time was 5.2 hours, robotic console time 2 hours, blood loss 50 ml and hospital
